Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?
03:20pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward
Here's Why You Should Retain Inari Medical (NARI) Stock Now
04:08pm, Monday, 29'th Aug 2022 Zacks Investment Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
03:45pm, Monday, 29'th Aug 2022 Zacks Investment Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
04:20pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
02:34pm, Thursday, 25'th Aug 2022 Benzinga
Upgrades
According to Goldman Sachs, the prior rating for FREYR Battery (NYSE:FREY) was changed from Neutral to Buy. In the second quarter, FREYR Battery showed an EPS of $0.24, compared to $0.04 from
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
04:56pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
02:18pm, Monday, 22'nd Aug 2022
Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.
4 Stocks to Watch Amid Recovering Medical Products Industry
12:32pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised
4 Stocks to Watch Amid Recovering Medical Products Industry
09:47am, Thursday, 18'th Aug 2022
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised
Thermo Fisher (TMO) Debuts Assay for Research on HIV Strains
01:01pm, Monday, 15'th Aug 2022 Zacks Investment Research
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
03:28pm, Friday, 29'th Jul 2022 Zacks Investment Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
02:02pm, Friday, 29'th Jul 2022
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript
09:52pm, Thursday, 28'th Jul 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President &
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
09:45pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
07:30pm, Thursday, 28'th Jul 2022
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
